TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14740095

Group type: EXPERIMENTAL
Intervention: Gadodiamide administration at 3 T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative triple-dose 3 T images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cumulative triple-dose 1.5 T images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR venography at 3 T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contrast-enhanced MR venography at 1.5 T
Number of subjects: 0
Study: 11161231

Group type: EXPERIMENTAL
Intervention: irinotecan/5-FU/LV
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 0
Study: 9581302

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg per day for 5 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (100 mg/kg per day for 5 days)
Number of subjects: 80
Study: 7800155

Group type: EXPERIMENTAL
Intervention: Moclobemide (up to 300 mg per day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 3050906

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg (single dose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg (2-dose regimen)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Acetaminophen 500 mg (2-dose regimen)
Number of subjects: 150
Study: 30607981

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) items analysis using Item Response Theory (IRT)
Number of subjects: 1873
Study: 31511920

Group type: EXPERIMENTAL
Intervention: Atlas-axis anteroposterior distance (AAAD)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Atlas-axis lateral distance (AALD)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Atlantoaxial lateral bending angle (AALB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Atlantoaxial rotation angle (AARA)
Number of subjects: 140
Study: 29940247

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 120
Study: 26514619

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) with sodium ferrous citrate (SFC) (100 and 115 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (CNT)
Number of subjects: 10
Study: 24450608

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (six booklets every fortnight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 22160495

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (2 g/day for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 38
Study: 21056806

Group type: EXPERIMENTAL
Intervention: Preemptive lidocaine 4 mL mixed with propofol 20 mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preemptive lidocaine 4 mL mixed with etomidate 20 mL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Simultaneous treatment with lidocaine 4 mL mixed with propofol 20 mL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Simultaneous treatment with lidocaine 4 mL mixed with etomidate 20 mL
Number of subjects: 80
Study: 17058270

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical MUNE method
Number of subjects: 0
Study: 16297689

Group type: EXPERIMENTAL
Intervention: 0.75 mg/mL rhBMP-2/ACS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.50 mg/mL rhBMP-2/ACS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bone graft
Number of subjects: 48
Study: 12185767

Group type: EXPERIMENTAL
Intervention: High stimulation mode of Vagus nerve stimulation (VNS)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Low stimulation mode of Vagus nerve stimulation (VNS)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 10000
Study: 9951675

Group type: EXPERIMENTAL
Intervention: BioComFold IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Foldable control IOL
Number of subjects: 30
Study: 7594348

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg q.d. plus ampicillin 500 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. plus ampicillin 500 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lansoprazole (82%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Famotidine (73%)
Number of subjects: 24
Study: 2130301

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 26
Study: 471256

Group type: EXPERIMENTAL
Intervention: Physical training (bicycle training and calisthenics, 40 sessions, 4 per week, starting 7-8 weeks after MI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (31 patients, uniform intervention on primary risk factors and medical therapy)
Number of subjects: 29
Study: 30728002

Group type: EXPERIMENTAL
Intervention: Culturally tailored SMS intervention (The Step One Program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic 'thank you' message (Control)
Number of subjects: 0
Study: 29160622

Group type: EXPERIMENTAL
Intervention: Pulsed irrigation evacuation (PIE)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 391

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 391
Study: 25581163

Group type: EXPERIMENTAL
Intervention: inchinkoto group, n = 30
Number of subjects: 61

Group type: COMPARATOR
Intervention: non-inchinkoto group, n = 31
Number of subjects: 61
Study: 24431382

Group type: EXPERIMENTAL
Intervention: Coronary stenting (from pooled data of 6 global randomized controlled trials: ENDEAVOR and SIRIUS programs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected predictors for MACCE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected predictors for VTE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ejection fraction and age
Number of subjects: 0
Study: 22522672

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg single dose (group B)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg every other day for 15 days (group C)
Number of subjects: 205

Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 205
Study: 19221595

Group type: EXPERIMENTAL
Intervention: Topical paromomycin (PR) with methylbenzethonium chloride (MBCL)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Topical paromomycin (PR)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Parenteral paromomycin (PR)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Topical or parenteral paromomycin (PR)
Number of subjects: 1221
Study: 17716994

Group type: EXPERIMENTAL
Intervention: Colorectal polypectomy
Number of subjects: 1673
Study: 14691431

Group type: EXPERIMENTAL
Intervention: Direct PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: t-PA
Number of subjects: 0
Study: 12538120

Group type: EXPERIMENTAL
Intervention: Direct aortic cannulation (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard femoral cannulation (group A)
Number of subjects: 20
Study: 9823137

Group type: EXPERIMENTAL
Intervention: Calcium-hydroxide paste
Number of subjects: 48

Group type: COMPARATOR
Intervention: Corticosteroid-antibiotic solution
Number of subjects: 48
Study: 7704924

Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (TOPV) given at birth, 6 weeks, 10 weeks, and 14 weeks after birth
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group omitted the dose at birth
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: TOPV immunization schedule starting at birth
Number of subjects: 452
Study: 2653972

Group type: EXPERIMENTAL
Intervention: Loperamide (2 mg capsules, two on entry and one after each unformed stool up to a maximum of eight per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 373661

Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate, 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ephedrine sulfate, 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aminophylline, 400 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31875646

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: GFRAL-antagonist antibody
Number of subjects: 0
Study: 31194950

Group type: EXPERIMENTAL
Intervention: IOL repositioning by scleral suturing
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IOL exchange by retropupillary fixation of an iris claw IOL
Number of subjects: 104
Study: 28118453

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 158
Study: 26466219

Group type: EXPERIMENTAL
Intervention: Ketamine (2.0mg/kg, max 70mg) associated with midazolam (0.2mg/kg, max 10mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Morphine (0.1mg/kg, max 5mg) associated with midazolam (0.2mg/kg, max 10mg)
Number of subjects: 25
Study: 24416905

Group type: EXPERIMENTAL
Intervention: Manipulation of Traditional Chinese Medicine (TCM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 62
Study: 17311247

Group type: EXPERIMENTAL
Intervention: Training in relaxation and guided imagery techniques
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (standard training regarding brachytherapy)
Number of subjects: 66
Study: 15240190

Group type: EXPERIMENTAL
Intervention: IFN beta-1b standard dose (250 microg every other day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: IFN beta-1a (30 microg once-a-week)
Number of subjects: 27
Study: 10813504

Group type: EXPERIMENTAL
Intervention: Schistosoma haematobium infection
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: Age and sex-specific prevalence of S. haematobium
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: History of hematuria
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: Physical examination for hepatomegaly and splenomegaly
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: Ultrasonography for hepatomegaly
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: Ultrasonography for splenomegaly
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: Grade III periportal fibrosis
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: Bladder wall lesions and obstructive uropathy
Number of subjects: 17822

Group type: EXPERIMENTAL
Intervention: S. mansoni prevalence
Number of subjects: 17822
Study: 8772552

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (100-400 ng/kg-day ethinyl estradiol)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 31
Study: 1434629

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 0
Study: 3901721

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30530597

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 100
Study: 27324320

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26198675

Group type: EXPERIMENTAL
Intervention: Decision aid for mammography screening
Number of subjects: 7400

Group type: COMPARATOR
Intervention: Usual care (invitation and standard leaflet of the mammography screening programme)
Number of subjects: 7400
Study: 25573347

Group type: EXPERIMENTAL
Intervention: Garlic powder tablet (1200 µg allicin/tab) twice daily for 3 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 56
Study: 21071683

Group type: EXPERIMENTAL
Intervention: Single-person mask ventilation using Laerdal self-inflating bag (SIB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Two-person mask ventilation using Laerdal self-inflating bag (SIB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single-person mask ventilation using Neopuff (NP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Two-person mask ventilation using Neopuff (NP)
Number of subjects: 48
Study: 19274696

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Benzyl benzoate lotion
Number of subjects: 35
Study: 16798793

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (1-ppm change)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (20-ppb change)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Sulfur dioxide (3-day moving sum)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Particulate matter (PM10)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Ozone
Number of subjects: 990
Study: 12717356

Group type: EXPERIMENTAL
Intervention: Minilaparotomy approach (n = 14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Retroperitoneal approach (n = 12)
Number of subjects: 26
Study: 11028944

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.2 mg at pH 4.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.2 mg at pH 7.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.2 mg at pH 9.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.4 mg at pH 4.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.4 mg at pH 7.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.4 mg at pH 9.0
Number of subjects: 0
Study: 9200654

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atenolol 50-100 mg/day
Number of subjects: 43
Study: 8256699

Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate 30, 60, 120 or 240 mg once daily
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Extended-release isosorbide mononitrate 120 or 240 mg once daily
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 2863998

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg/kg (group A; n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fazadinium 1 mg/kg (group F; n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (pre-induction values)
Number of subjects: 22
Study: 30985571

Group type: EXPERIMENTAL
Intervention: Modic changes (MCs) group
Number of subjects: 204

Group type: COMPARATOR
Intervention: No Modic changes (non-MCs) group
Number of subjects: 204
Study: 28474361

Group type: EXPERIMENTAL
Intervention: Virtual Consultation (VC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Face-to-Face (F2F)
Number of subjects: 70
Study: 26907485

Group type: EXPERIMENTAL
Intervention: Written educational material (intervention group, n=28)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Biopsy only group (n=25)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group without biopsy (n=30)
Number of subjects: 83
Study: 25040799

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 3 g a day
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 23140829

Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization (THD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: LigaSure
Number of subjects: 114
Study: 20109864

Group type: EXPERIMENTAL
Intervention: Catheter ablation and an ICD (ablation group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: ICD alone (control group)
Number of subjects: 110
Study: 18006568

Group type: EXPERIMENTAL
Intervention: BiliMed (Medick SA, Paris, France)
Number of subjects: 686

Group type: COMPARATOR
Intervention: BiliCheck (Respironics, Marietta, GA, USA)
Number of subjects: 686
Study: 16100174

Group type: EXPERIMENTAL
Intervention: nCPAP (10 cm H2O for 12 to 24 h)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment (intermittent nCPAP 10 cm H2O for 10 min every 4 h)
Number of subjects: 56
Study: 12052996

Group type: EXPERIMENTAL
Intervention: Coupled protocol of EMG-triggered stimulation and bilateral movement (n=10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: EMG-triggered stimulation and unilateral movement (n=10)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 25
Study: 10598196

Group type: EXPERIMENTAL
Intervention: Video-assisted parathyroidectomy (VAP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional cervicotomy
Number of subjects: 38
Study: 8583185

Group type: EXPERIMENTAL
Intervention: Routine breast screening with mammograms and physical examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine breast screening with mammography and physical examination
Number of subjects: 0
Study: 1755531

Group type: EXPERIMENTAL
Intervention: NLA in combination with epidural opiate analgesia (group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: NLA in combination with local anesthesia (group 3)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Neuroleptanesthesia (NLA) (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidurally administered morphine (group 2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural local anesthetics (group 3)
Number of subjects: 28
Study: 6804222

Group type: EXPERIMENTAL
Intervention: 60 mg DPM (dipropylacetamide) taken after a standard meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: 60 mg DPM (dipropylacetamide) taken in a fasting state
Number of subjects: 6
Study: 31038276

Group type: EXPERIMENTAL
Intervention: Haemostatic sealant
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care (bipolar coagulation)
Number of subjects: 94
Study: 28716313

Group type: EXPERIMENTAL
Intervention: Telemedicine (myIBDcoach)
Number of subjects: 909

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 909
Study: 25620717

Group type: EXPERIMENTAL
Intervention: Servomatic A and B
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: E‐motion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pushrim-activated power-assisted wheelchairs (PAPAWs)
Number of subjects: 52
Study: 25042182

Group type: EXPERIMENTAL
Intervention: Ataluren 10, 10, 20 mg/kg
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 22550833

Group type: EXPERIMENTAL
Intervention: High dose pantoprazole bolus injections (40 mg twice daily for 7 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of pantoprazole (8 mg per hour for first 3 days, then 40 mg bolus twice daily for 4-7 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High dose pantoprazole bolus injections
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of pantoprazole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 19961732

Group type: EXPERIMENTAL
Intervention: Dipyridamole (201)Tl SPECT myocardial imaging (group 1, n = 35)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Exercise myocardial (99)Tc(m)-MIBI SPECT imaging (group 2, n = 28)
Number of subjects: 63
Study: 17086540

Group type: EXPERIMENTAL
Intervention: Dysfunctional Attitude Scale (DAS) scores at the beginning of the continuation phase
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dysfunctional Attitude Scale (DAS) scores at the beginning of continuation treatment
Number of subjects: 64
Study: 15022126

Group type: EXPERIMENTAL
Intervention: Once-daily 2.5-mg rhDNase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alternate-day 2.5-mg rhDNase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-daily 5 ml of 7% hypertonic saline (HS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 48
Study: 11265078

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU)
Number of subjects: 41

Group type: COMPARATOR
Intervention: CT scanning
Number of subjects: 41
Study: 9772930

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once daily for 8 weeks
Number of subjects: 16987

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once daily for 4 weeks, then Hydrochlorothiazide 12.5 mg once daily for the last 4 weeks if DBP > 90 mmHg
Number of subjects: 16987

Group type: EXPERIMENTAL
Intervention: Benazepril alone or associated with Hydrochlorothiazide
Number of subjects: 16987
Study: 8170729

Group type: EXPERIMENTAL
Intervention: PRP-T with diphtheria toxoid vaccine
Number of subjects: 146

Group type: COMPARATOR
Intervention: PRP-OMP with diphtheria-tetanus toxoid vaccine
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: PRP-T
Number of subjects: 146

Group type: COMPARATOR
Intervention: PRP-OMP
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus toxoid vaccine
Number of subjects: 146
Study: 3336263

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Both adenoidectomy and tympanostomy tubes
Number of subjects: 476

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 476

Group type: COMPARATOR
Intervention: Tympanostomy tubes
Number of subjects: 476
Study: 30709606

Group type: EXPERIMENTAL
Intervention: Head of Bed Elevation (HBE) at 30° for 20 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head of Bed Elevation (HBE) at 45° for 20 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical collar (c-collar)
Number of subjects: 0
Study: 29132380

Group type: EXPERIMENTAL
Intervention: Standard government guidance with active enhancement of TB-HIV care integration through a quality improvement approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard government guidance for TB-HIV integration
Number of subjects: 40
Study: 26601519

Group type: EXPERIMENTAL
Intervention: cytoflavin during operation and in early postoperative period
Number of subjects: 90
Study: 24169352

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 518

Group type: COMPARATOR
Intervention: SLNB followed by ALND
Number of subjects: 518
Study: 20603243

Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy (QOLT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Supportive Therapy (ST)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 62